Non-nucleoside reverse transcriptase inhibitors

Missed opportunities for participation in prevention of mother to child transmission programmes: Simplicity of nevirapine does not necessarily lead to optimal uptake, a qualitative study

The objective of this study was to examine missed opportunities for participation in a prevention of mother-to-child transmission (PMTCT) programme in three sites in South Africa. A rapid anthropological assessment was used to collect in-depth data from 58 HIV-positive women who were enrolled in a larger cohort study to assess mother-to-child HIV transmission. Semi-structured interviews were conducted with the women in order to gain an understanding of their experiences of antenatal care and to identify missed opportunities for participation in PMTCT.

WHO issues paediatric HIV treatment guidelines for low-income countries

Detailed guidelines for the treatment of infants and children in resource-limited settings have been issued this week by the World Health Organization ahead of the World AIDS Conference next week in Toronto. The guidelines highlight the difficulties in determining drug doses for children, and urge pharmaceutical companies to work towards producing fixed dose combinations that can be used to treat children.

CROI: Good responses to ART seen in women given nevirapine for mother to child transmission

Prior exposure to single-dose nevirapine (sdNVP, Viramune) for the prevention of mother-to-child transmission (PMTCT) does not necessarily impair a womans subsequent response to nevirapine-containing antiretroviral treatment (ART), particularly if enough time passes between that exposure and the need for ART, according to studies presented at the Thirteenth Conference on Retroviruses and Opportunistic Infections in Denver. The studies suggest that nevirapine-containing regimens are still a good first-line option for ART for many sdNVP-exposed women in resource-limited settings.

Single dose nevirapine for mother doesn't lead to worse CD4 response to HAART

Women who took a single dose of the non-nucleoside analogue (NNRTI), nevirapine (Viramune) to prevent mother-to-baby transmission of HIV have an immunological response to HAART comparable to women who did not use nevirapine in this way, according to a study presented to the Third International AIDS Society Conference on HIV Pathogenesis and Treatment in Rio de Janeiro on July 25th.

Use of AIDS Medicine Might Be Altered to Avert Drug Resistance

BOSTON, Feb. 24 -- AIDS experts have reached the conclusion that nevirapine, the workhorse drug that has prevented tens of thousands of cases of HIV infection in newborn babies, has enough drawbacks that its use is likely to change markedly.

Combination Therapy Might Be Better Choice Than Nevirapine Alone To Prevent Vertical HIV Transmission, Researchers Say

Antiretroviral drug combination therapy might be more effective in preventing mother-to-child HIV transmission and less likely to foster drug resistance among pregnant women than single-dose nevirapine, according to data presented this week at the... 12th Conference on Retroviruses and Opportunistic Infections in Boston, the Washington Post reports.